Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-279-4 | CAS number: 10102-90-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
For further information please refer to read across justification in IUCLID section 13. - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Type:
- other: toxicokinetics
- Results:
- The absorption, distribution and excretion of copper is dependent on the level of copper intake. The toxicokinetic behaviour of several inorganic copper salts is comparable and therefore also applicable to dicopper hydroxide phosphate.
- Metabolites identified:
- no
- Conclusions:
- By using a weight of evidence approach it is demonstrated that the absorption, distribution and excretion of copper is dependent on the level of copper intake. Moreover, evaluation of the whole data base reveals that the toxicokinetic behaviour of several inorganic copper salts is comparable and therefore also applicable to dicopper hydroxide phosphate.
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
For further information please refer to read across justification in IUCLID section 13. - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Remarks on result:
- other:
- Remarks:
- By using a weight of evidence approach it is demonstrated that percutaneous absorption of copper is < 6 % of the applied dose independent of the substance applied. Formulations increased the copper concentrations in whole skin.
- Conclusions:
- By using a weight of evidence approach it is demonstrated that percutaneous absorption of copper is < 6 % of the applied dose independent of the substance applied. Formulations increased the copper concentrations in whole skin. It was considered that the increase in Cu concentration in whole skin may have been due to a build-up of Cu in epidermis, in effect forming a Cu reservoir, followed by slow diffusion through the dermis.
Referenceopen allclose all
Description of key information
By using a weight of evidence approach it is demonstrated that the absorption, distribution and excretion of copper is dependent on the level of copper intake. Moreover, evaluation of the whole data base reveals that the toxicokinetic behaviour of several inorganic copper salts is comparable and therefore also applicable to Copper (II) pyrophosphate.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Toxicokinetics, metabolism and distribution
There is one GLP study according to OECD TG 417 available (Himmelstein, 2003). Within this study it could be demonstrated that several copper salts (copper hydroxide, copper oxide, copper oxychloride, tribasic copper sulphate and Bordeaux Mixture) were similarly absorbed to copper sulphate following oral administration. The absorbed dose ranged from 10.7 to 12.9 % based on percent of the dose measured in whole blood, liver, carcass, bile and urine. The ranking of copper concentrations in excreta and tissue samples was generally faeces > GI tissue and contents (post-biliary) > stomach and contents > liver > bile > plasma ~ whole blood ~ carcass > urine. After termination of the study a complete clearance of administered Cu was observed.
Due to the fact that the water solubility of Copper (II) pyrophosphate is between the water solubility of copper hydroxide and copper sulphate pentahydrate a comparable toxicokinetic behaviour of Copper (II) pyrophosphate is considered.
These assumptions are supported by a number of studies which have been performed on analogous substances. These studies are considered to provide useful data for assessing the toxicokinetics of Copper (II) pyrophosphate.
Besides the studies available in the IUCLID dossier a Conclusion on the peer review of copper compounds (EFSA Scientific Report(2008) 187, 1-101) is publicly available. The following considerations for copper as a micronutrient are highlighted within this review:
Copper has been the subject of extensive research. It is widely distributed in biological tissues, where it occurs largely in the form of organic complexes, many of which are metalloproteins and function as enzymes. Copper enzymes are involved in a variety of metabolic reactions, such as the utilization of oxygen during cell respiration and energy utilization. They are also involved in the synthesis of essential compounds, such as the complex protein of connective tissues of the skeleton and blood vessels, and in a range of neuroactive compounds concerned in nervous tissue function. Copper is present in almost all foods, most human diets naturally include between 1 to 2 mg/person/day of copper, with some containing up to 4 mg/person/day. Copper levels in blood and tissues are generally stable; the body is able to maintain a balance of dietary copper intake and excretion that allows normal physiological processes to take place. Up to 93 % of the copper in the blood is bound to the enzyme caeruloplasmin, while the majority of the rest are bound to albumin and amino acids; there is strong evidence that absorbed copper is never released free in the blood or in the cells.
A bioequivalence study (Himmelstein, 2003) was performed to compare the five variants of copper, copper hydroxide, copper oxychloride, Bordeaux mixture, tribasic copper sulphate and copper (I) oxide with copper sulphate pentahydrate on bile cannulated rats to demonstrate that toxicological studies on copper sulphate could be used in the toxicological risk assessment of the five variants. Absorption, distribution and excretion rates were similar between the six variants of copper following oral ingestion of 20 mg Cu/kg bw; liver was the principal organ of regulation of copper, and main excretion was via the bile. Liver copper levels increased significantly following dosing with Tmax at 12 hours; depuration was rapid, with levels returning to control by 48 hours after dosing. Plasma concentrations in both control and dosed rats remained unchanged. These findings were consistent with the homeostatic bio-regulation of copper found in the open literature. Oral absorption of copper varies according to the diet; for humans a copper-adequate diet results in 36 % absorption, while a low-copper diet results in 56 % absorption and a high-copper diet in 12 % absorption. Similar figures were found in rat; 50 % oral absorption was considered for this species.
Distribution occurs directly from the intestine to the liver, which controls the distribution of copper to the rest of the body via the bloodstream, bound to caeruloplasmin. Metabolism does not occur. Copper does not accumulate, except in cases of genetic disease or chronic administration of high doses, where copper accumulates in the liver. Excretion is rapid, via the bile, in a trypsin-independent protein fragment, therefore entero-hepatic circulation does not occur. Significant amounts of copper are excreted bound to metallothioneins contained in intestinal brush border cells, sloughed off and lost in faeces; minor amounts are also excreted in urine and from skin and hair.
Dermal absorption
By using a weight of evidence approach it is demonstrated that percutaneous absorption of copper containing formulations is very low: 0.1 to 6 % of the applied dose.
Besides the studies available in the IUCLID dossier a Conclusion on the peer review of copper compounds (EFSA Scientific Report(2008) 187, 1-101) is publicly available. The following considerations for copper are highlighted within this review:
An in vitro percutaneous absorption study of copper was performed with the five representative variants of copper (I) and (II). However, the study reported that up to 25 tape strips were used to remove the stratum corneum and discarded. Therefore, no information on the amounts present in tape strips was available. The experts agreed to set the dermal absorption as a 10 % conservative default value (for the concentrate and the in-use spray dilution), based on the lack of information on the tape strips amounts and having in mind the relatively low percentage of oral absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.